THERAPEUTICS CEO DEMONSTRATES HOW 1
MILLION MICRODOSES OF LSD CAN POTENTIALLY BE USED TO TREAT
Microdoses used to create proprietary microdosing
scientists take delivery of GMP grade LSD
clinical trial repository of biometric, physiological and
psychometric data for Microdosing in a big data play for
British Columbia – May 30, 2023 – MindBio Therapeutics Corp.
(CSE: MBIO); (Frankfurt: WF6), (the "Company"
Chief Executive Officer Justin
Hanka demonstrates how 1 million microdoses of LSD could
potentially benefit tens of thousands of patients with
All pharmaceutical medicines need
to be made to the standard of Good Manufacturing Practices (GMP)
which require manufacturers to ensure that their products are
traceable, safe, pure and effective for human consumption.
MindBio's CEO recently visited its manufacturer in Canada that is
fully licensed by the Canadian Government to manufacture GMP grade
LSD for the pharmaceutical industry. At the time of the visit the
manufacturer had just produced the LSD that would be shipped to
MindBio for its Phase 2 Clinical Trials.
The GMP grade LSD seen in these
jars is used to create a novel sublingual formulation for
LSD-microdosing that allows patients to titrate their
The formulation has long shelf
life and is designed to be stored and used at
Chief Executive Officer inspects GMP grade LSD to be used in
MindBio's Phase 2 LSD-Microdosing clinical trials.
Through a secure chain of
custody, MindBio is pleased to announce the GMP LSD has safely and
securely arrived at our labs for processing in preparation for both
Phase 2 Clinical Trials.
MindBio's clinical trials have
obtained regulatory approvals for at-home use of LSD. At-home use
is crucial for testing and modeling the safety and efficacy of
psychedelics within the community, as we strive to have these
life-saving medicines approved. MindBio's landmark Phase 1 LSD-Microdosing
clinical trial completed in 2022 showed no serious adverse events,
and participants in the LSD-Microdosing treatment group reported
statistically significant increases in feelings of happiness,
social connectivity, wellness, creativity, and energy compared to
the placebo group.
Chief Executive Officer and
Co-founder of MindBio said "By using microdosing, we are creating a
unique treatment model that is globally scalable, accessible, and
affordable, aiming to address the existing challenges in mental
health care. MindBio is amassing the world's largest repository of
biometric, physiological and psychometric data from Microdosing
randomised controlled clinical trials in a big data play for the
Company. We are leading the world in LSD-Microdosing and look
forward to providing the next update to shareholders
We invite you to join us in support of
creating a brighter future for mental health.
Receive our latest updates
MindBio on LinkedIn: https://www.linkedin.com/company/mindbio-therapeutics/?viewAsMember=true
CEO Justin Hanka on LinkedIn: https://www.linkedin.com/in/justinhanka/
further information, please contact:
Hanka, Chief Executive Officer
MindBio is a biotech/biopharma
company focused on creating novel and emerging treatments for
mental health conditions and is conducting world first take-home
LSD-Microdosing human clinical trials. MindBio is a leader in microdosing of
psychedelic medicines and is advancing its drug and technology
protocols through clinical trials. MindBio has developed a
multi-disciplinary platform for developing treatments and is
involved in psychedelic medicine development and digital
therapeutics, has completed Phase 1 clinical trials microdosing
Lysergic Acid Diethylamide (LSD) in 80 patients, has a Phase 2
clinical trial in development microdosing LSD in patients with
Major Depressive Disorder and a Phase 2 clinical trial in
development microdosing LSD in late stage cancer patients
experiencing existential distress. MindBio invests in research that
forms the basis for developing novel and clinically proven
treatments including digital technologies and interventions to
treat debilitating health conditions such as depression, anxiety
and other related mental health conditions.
Note Concerning Forward-Looking Statements:
The press release contains
"forward-looking statements" within the meaning of applicable
securities laws. Forward-looking statements can be identified by
words such as: "anticipate," "intend," "plan," "budget," "believe,"
"project," "estimate," "expect," "scheduled," "forecast,"
"strategy," "future," "likely," "may," "to be," "could," "would,"
"should," "will" and similar references to future periods or the
negative or comparable terminology, as well as terms usually used
in the future and conditional. Forward-looking statements are based
on assumptions as of the date they are provided. However, there can
be no assurance that such assumptions will reflect the actual
outcome of such items or factors.
Additionally, there are known and
unknown risk factors that could cause the Company's actual results
and financial conditions to differ materially from those indicated
in the forward-looking statements. Therefore, you should not rely
on any of these forward-looking statements. Important risk factors
that could cause actual results and financial conditions to differ
materially from those indicated in the forward-looking statements,
include among others: general economic, market and business
conditions in Canada and Australia; market volatility; unforeseen
delays in timelines for any of the transactions or events described
in this press release. All forward-looking information is qualified
in its entirety by this cautionary statement.
The Company disclaims any
obligation to revise or update any such forward-looking statement
or to publicly announce the result of any revisions to any of the
forward-looking information contained herein to reflect future
results, events or developments, except as required by
Neither the Canadian Securities
Exchange nor its Regulation Service Provider (as that term is
defined in the policies of the Canadian Securities Exchange)
accepts responsibility for the adequacy or accuracy of this